Multiple myeloma: the present and the future.
Major advances continue apace in therapy and in understanding its molecular pathogenesis.
Joshua
Douglas E
DE
D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001847:Bone Diseases / Q000209:etiology / Q000628:therapy; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008495:Medical Oncology / Q000639:trends*; D008558:Melphalan / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D011480:Protease Inhibitors / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use; D033581:Stem Cell Transplantation / Q000379:methods; D013792:Thalidomide / Q000627:therapeutic use; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D001897:Boronic Acids; D004164:Diphosphonates; D007166:Immunosuppressive Agents; D011480:Protease Inhibitors; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D008558:Melphalan